

September 2, 2022 | Issue 236

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

> Subscribe here



Healthcare regulatory news

CMS released a proposed rule to <u>streamline Medicaid and CHIP enrollment</u>, establishing consistent renewal policies and processes across states, including limiting renewals to once every twelve months.

CMS' Medicare Shared Savings Program (MSSP) 2021 results show <u>58% of Accountable Care Organizations (ACOs) generated shared savings</u>, totaling \$1.6B in Medicare spending.

HHS announced its <u>largest investment ever (\$98.9M) in health insurance Navigators</u> ahead of Open Enrollment 2023...HHS announced <u>\$79M investment to expand Substance Use Disorder treatment</u> and prevention...HRSA announced a <u>\$20M investment to reduce disparities in maternal and infant health</u>.

DOL reported <u>arbitrators have rendered determinations on just 1,200 of 46,000 cases</u> submitted to the *No Surprises Act* dispute portal since April 15th.



Healthcare law and policy news

KaufmanHall reported <u>July hospital operating margins are the lowest</u> in the pandemic period... Fitch Ratings mid-year report downgraded the <u>outlook for the non-profit health sector from "neutral" to "deteriorating" following ongoing staffing issues and unpredictable patient volume.</u>

Astra Zeneca's Farxiga phase III clinical trial analysis demonstrated <u>14% reduction in cardiovascular death</u> among heart failure patients.

JAMA studies found: (1) only modest improvements in mean quality measures associated with higher Medicare Advantage premiums; (2) receipt of emergency-telehealth-waiver-expanded services improved opioid use disorder outcomes in Medicare patients.

A new study found <u>Nurse Practitioners and Physician Assistants</u> hold a majority of U.S. primary care roles (51%).

Advocacy groups filed a <u>lawsuit</u> alleging a 2020 HHS/CMS rule illegally limits patients from using copay assistance.

Florida filed a suit against the <u>FDA for unlawfully delaying action on Florida's application to import</u> Canadian prescription drugs.

Wellstar Health announced plans to close Atlanta Medical Center Nov 1st, the health system's second closure in six months.

Illumina prevailed in an FTC antitrust lawsuit seeking to unwind the company's \$7B acquisition of cancer startup Grail.

Ocean Biomedical announced a \$345M merger with Aesther Healthcare Acquisition Corp, a special acquisition corporation (SPAC)... InterWell Health finalized a \$2.4B merger with Fresenius Health Partners and Cricket Health forming a value-based kidney care company...Walgreens Boots Alliance completed its \$330M acquisition of at-home-care tech platform CareCentrix.

George Washington University data indicate over <u>half of U.S. counties have no active psychiatrist or</u> addiction medicine specialist.

Special Section: COVID-19 and Monkeypox News

New data from the Centers for Disease Control (CDC) show evidence of racial and ethnic disparities in Monkeypox vaccine distribution—only 10% of doses have been distributed to Black patients when they account for one third of all U.S. cases.

HHS Biomedical Advanced Research and Development Authority (<u>BARDA</u>) will provide <u>\$11M to support domestic production of Smallpox and Monkeypox vaccines.</u>

Texas health officials confirmed the first known death attributed to Monkeypox in the U.S.

CDC data revealed U.S. life expectancy at birth declined for second consecutive year, COVID-19 cited as main driver.

FDA authorized emergency use of updated COVID-19 booster vaccines from Pfizer-BioNTech and Moderna.

ASPR Secretary Dawn O'Connell signaled that funds for free COVID-19 vaccines may run out as early as January 2023.

GAO report found that hospitals were unprepared to deal with COVID-19 surges, despite participating in HHS readiness activities.

Vaxart, released positive Phase 2 clinical trial data on its oral COVID-19 vaccine, the first oral COVID-19 vaccine candidate to conclude a Phase 2 trial.



Questions or comments, please send to us-hcinsight@kpmg.com.

kpmg.com/socialmedia











Privacy | Legal

This email was sent by KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2022 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.